VISEN Pharmaceuticals

Visen Pharmaceuticals is an innovative biopharmaceutical company dedicated to providing innovative therapies and compassionate, patient-centric care for endocrine diseases. Their focus on endocrine diseases in adults and children, and rare endocrine diseases reflects their commitment to addressing diverse patient needs. The company's global expertise and strength in endocrine therapies is exemplified by their team of seasoned professionals with multinational pharmaceutical experiences and their leveraging of cutting-edge technologies and leading resources across the world. Establishing themselves firmly in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, and a state-of-the-art R&D and manufacturing site in Suzhou, reflects their commitment to enhancing R&D, manufacturing, and commercialization efforts. This positioning aims to enable Chinese endocrine patients to benefit from advanced treatment solutions earlier, reflecting a patient-centric approach. In 2018, Visen Pharmaceuticals was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (with participation by Sofinnova Ventures), to develop and commercialize Ascendis Pharma's endocrinology therapies in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. Their recent $150 million Series B financing led by Sequoia China in January 2021 with participation from OrbiMed, Sherpa Healthcare Partners, Cormorant, HBM Healthcare Investments, Pivotal bioVenture Partners China, Logos Capital, and CDG Capital, alongside existing investors, including Ascendis Pharma A/S, Vivo Capital, and Sofinnova Investments, signifies a strong vote of confidence from the investor community. This substantial investment underlines the potential and progress of Visen Pharmaceuticals in advancing endocrine therapies and expanding their impact in Greater China.